SciBase study highlights Nevisense potential for AD prediction
Study published in Allergy found higher neonatal EIS scores linked to atopic dermatitis development in first year.
See the latest news and media coverage for SciBase. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of AI-based solutions for skin disorders
scibase.comLast updated
In short: SciBase expanded its Nevisense technology applications, secured FDA labeling extensions, and achieved record sales growth while raising capital.
Study published in Allergy found higher neonatal EIS scores linked to atopic dermatitis development in first year.
The reverse share split will reduce shares from 1,022,530,000 to 10,225,300.
It also re-elected board members, authorized a 1:100 reverse split and stock option program.
Overall sales increased 61% (80% adjusted). U.S. skin cancer sales rose 109%. Castle collaboration progresses as planned.
SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that ...
Today, the annual general meeting 2026 has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance with...
SciBase published the annual report for 2025.
Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to the annual general meeting to be held on 19 May...
Track SciBase and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.